TECHWIRE 30
(CIX: WRAL30)  1,147.54  up arrow+9.81  (0.86 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: Apple)  119.00  up arrow+1.4  (1.19 %)  Updated: 08:10 PM EST, Nov 26 2014
(NY: QUINTILES)  57.96  up arrow+0.21  (0.36 %)  Updated: 06:40 PM EST, Nov 26 2014
(OP: BASF SE)  94.20  up arrow+1.08  (1.15 %)  Updated: 05:20 PM EST, Nov 26 2014
(NQ: BioCryst)  11.38  up arrow+0.22  (1.97 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: BioDelivery)  15.80  up arrow+0.85  (5.69 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: CEMP)  14.54  up arrow+0.64  (4.6 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: Cisco Systems)  27.43  up arrow+0.15  (0.53 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: Cree)  36.74  up arrow+0.28  (0.77 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: DARA)  0.78  up arrow+0.02  (2.16 %)  Updated: 08:10 PM EST, Nov 26 2014
(NY: EMC CORPORATION)  30.04  up arrow+0.15  (0.5 %)  Updated: 06:40 PM EST, Nov 26 2014
(NQ: Extreme Networks)  3.63  down arrow-0.03  (-0.82 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: FB)  77.62  up arrow+1.99  (2.63 %)  Updated: 08:10 PM EST, Nov 26 2014
(NY: GLAXOSMITHKLINE)  46.52  up arrow+0.24  (0.52 %)  Updated: 06:40 PM EST, Nov 26 2014
(NQ: GOOG)  540.37  down arrow-0.71  (-0.13 %)  Updated: 08:10 PM EST, Nov 26 2014
(NY: IBM)  161.95  up arrow+0.19  (0.12 %)  Updated: 06:40 PM EST, Nov 26 2014
(NY: LH)  102.15  up arrow+1.62  (1.61 %)  Updated: 06:40 PM EST, Nov 26 2014
(OP: Lenovo Group)  27.89  up arrow+0.41  (1.49 %)  Updated: 05:20 PM EST, Nov 26 2014
(NY: MRK)  59.75  up arrow+0.41  (0.69 %)  Updated: 06:40 PM EST, Nov 26 2014
(NQ: Microsoft Corp)  47.75  up arrow+0.28  (0.59 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: NTAP)  42.70  down arrow-0.38  (-0.88 %)  Updated: 08:10 PM EST, Nov 26 2014
(NY: NOVARTIS AG)  95.56  up arrow+0.52  (0.55 %)  Updated: 06:40 PM EST, Nov 26 2014
(OP: Novozymes A/S)  45.82  down arrow-0.36  (-0.77 %)  Updated: 05:20 PM EST, Nov 26 2014
(NY: PFIZER)  31.10  up arrow+0.63  (2.07 %)  Updated: 06:40 PM EST, Nov 26 2014
(NQ: Pozen)  9.00  up arrow+0.03  (0.33 %)  Updated: 08:10 PM EST, Nov 26 2014
(NY: RED HAT)  62.10  up arrow+0.1  (0.16 %)  Updated: 06:40 PM EST, Nov 26 2014
(NQ: BBRY)  10.48  up arrow+0.12  (1.16 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: Salix)  103.25  up arrow+0.91  (0.89 %)  Updated: 08:10 PM EST, Nov 26 2014
(NQ: SQI)  15.25  up arrow+0.35  (2.35 %)  Updated: 08:10 PM EST, Nov 26 2014

Posts tagged “Quintiles”

Updated November 14

Report: Clinical trials for new drugs need more diversity in participants

A new report says 895 clinical trials for new drugs targeting a wide variety of diseases are underway in North Carolina. But the "Research in Your Backyard" report says greater diversity in races, ages, sex and sexual orientation are needed.

Clinical trials underway in N.C. Clinical trials underway in N.C.

November 10

Quintiles, Metabolon CEOs headline CED biotech conference; diversity in emojis?; AT&T hiring in Triangle; AT&T's big buy; YouTube amends copyright

Bulldog In today's Bulldog wrapup of technology and life science news: The CEO of Quintiles along with the CEO of Metabolon headline the CED's biotech conference; Those emojis you like to use may soon come in colors; AT&T is hiring in Raleigh; AT&T making a big buy in Mexico; and YouTube amends copyright form.

November 5

Premium Lock Quintiles buying $250M in shares; investors selling 13 million

Quintiles        Founder Dennis Gillings and other key investors are selling 13 million shares in Quintiles, and the world's largest life science services firm is buying $250 million of them through an underwriter. The deal means Quintiles' big investors now own less than 50 percent of the company and some changes in governance are coming as a result, a spokesperson says.

Updated October 31

Premium Lock CEO: Look for Quintiles to take more firms 'under our wing'

Quintiles CEO Tom Pike is on the lookout for more acquisitions. In a quarterly earnings conference call Thursday, Pike said the world's largest life science services company is on the "lookout" to put acquisition targets "under our wing." Our Insider subscribers get the details.

Tom Pike Tom Pike

October 30

Premium Lock Quintiles beats Street, ups its earnings forecast

Quintiles        Quintiles meets Wall Street expectations for revenues but tops those same forecasts in earnings by a penny a share. The global life science services firm also ups its earnings forecast.

Updated October 9

Premium Lock Quintiles exec: Reduce clinical trial timelines to speed up drug, vaccine development

In the midst of the deadly Ebola outbreak and the rushing to trial of experimental treatments, the world's top life sciences services company is calling for faster drug and vaccine development. In a 21st Century Cures Initiative discussion hosted by Rep. Renee Ellmers on Thursday, the head of the Phase 1 Clinical Research Division at Quintiles, said Phase 1 trial "timelines" should be reduced by "addressing inefficiencies and redundancies." Quintiles has helped develop and commercialize all of the world's top 100 selling drugs in 2013.

Developing vaccines Developing vaccines

Updated October 6

Premium Lock Quintiles shutting down its continuing education business

Quintiles        Quintiles, the world's largest life science services company, is closing down its medical education business, the company tells WRAL TechWire, as part of a reorganization.

Updated July 31

Premium Lock Next wave in clinical trials? Risk-based monitoring, says Quintiles CEO

Tom Pike, CEO of Quintiles, sees a new wave of business coming for life science services companies. And the world's largest contract research organization is ready to capitalize on "risk-based monitoring," he says in a conference call.

Tom Pike Tom Pike

Updated July 31

Premium Lock As earnings soar, Quintiles ups expectations for 2014

Quintiles        Quintiles, the world's largest life science company, says new business surged 21 percent in its most recent quarter, driving revenues to $1.035 billion compared to $944 million a year ago. Earnings jumped 30 percent to 65 cents per share. Quintiles also adjusted upward its financial expectations for the year.

Updated July 3

Premium Lock Pozen resubmits drug; Amazon to fight FTC; Furiex, Quintiles deals close; Twitter's new CFO

Bulldog In today's Bulldog wrapup of technology and life science news: Pozen resubmits a drug application; Amazon to fight FTC over kid apps purchases; Furiex and Quintiles deals close; Twitter names a new CFO

June 23

Premium Lock Carolinas HealthCare, SAS and Quintiles named Best Places to Work in IT

2014 Computerworld Best Places to Work in IT Every year since 1994, Computerworld has published a list of the 100 Best Places to Work in IT. On Monday, the publication released this year's list.

June 23

Premium Lock Opinion: Pharma follows as the CROs fly

Contract research organizations aren't what they used to be. But, they are where they used to be: in North Carolina.

NC the CRO Epicenter? NC the CRO Epicenter?

June 13

Premium Lock Pharma outsourcing beyond clinical trials paves way for more Quintiles growth

Quintiles CEO Tom Pike says Quintiles' ability to offer pharmas more than simply outsourced clinical trial services will lead to the company's growth. Read more about his comments to analysts and investors at Goldman Sach's healthcare conference.

Quintiles' Goldman Sachs 2014 presentation Quintiles' Goldman Sachs 2014 presentation

June 9

Premium Lock ISR recognizes Quintiles as leader in clinical research services

Quintiles        The contract research organization continues to rack up accolades this month with a new survey from ISR out on Monday that taps Quintiles as an industry leader in Phase I clinical research services.

June 6

Premium Lock Quintiles cracks Chief Information Officer 100 list

Quintiles        Quintiles, the world's largest life science services company, is adding another honor. After being named to the Fortune 500 earlier this week, Quintiles on Friday was selected for the CIO 100 list for information technology innovation.

Updated June 2

Premium Lock Quintiles named to Fortune 500

Quintiles        Quintiles, the Triangle-based international biopharmaceutical giant, was named Monday to the Fortune 500 list of largest U.S. companies ranked by revenue.

Updated May 13

Premium Lock Inside Quintiles' new acquisition: Why make the deal for Encore? Don't expect jobs to move to RTP

Quintiles        Quintiles CEO Tom Pike has said in the past that the world's largest life science services company would keep making acquisitions after going public a year ago. True to his word, Pike is growing Quintiles again in a deal for Houston-based Encore. How does the deal boost the big "Q"? By the way, don't expect any jobs to move to N.C. WRAL TechWire Insiders find out.

Updated May 13

Premium Lock Quintiles acquires 300-employee health information analytics firm

Electronic health records Quintiles, the world's largest provider of life science industry services, is growing a bit bigger but adding more expertise in healthcare analytics through the acquisition of Encore Health Resources.

April 29

Premium Lock From our archives: The Fred Eshelman saga includes one-person startup at PPD to Wilmington's Walk of Fame and now a $1.1B sale of Furiex

Fred Eshelman Looking back at Fred Eshelman's career: A 2009 blog post recapped a tumultuous year for Eshelman and PPD in which the company's stock was hammered and he stepped down as CEO to become executive chairman. But the year was capped with a salute. From there, Eshelman has continued to make headlines.

Updated April 24

Premium Lock Quintiles, Biogen strike 5-year drug development deal

Quintiles, the world's largest provider of life science services such as clinical trials, and pharmaceutical firm Biogen, which has a huge manufacturing facility in RTP, have formed a "collaboration" through which the two firms will develop drug candidates in Biogen's pipeline. But neither company will discuss financial terms of the deal. There may be some hiring at Quintiles for a Biogen-focused team, but Biogen plans no layoffs.

Quintiles teams with Biogen Quintiles teams with Biogen

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll